In November 2004, the FDA approved Genzyme Corporation's Captique (tm),
which was described in the official press release as:
"the newest hyaluronic acid entry into the U.S. dermal filler marketplace. It is indicated for the correction of moderate to severe facial wrinkles and is manufactured by Genzyme. Inamed is Genzyme's exclusive U.S. marketing and distribution partner for Captique."
The official trademark application (filed on March 1, 2004 by Genzyme) for Captique (tm) reads:
"CAPTIQUE: pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, scars, lines, and furrows"
Inamed is the only authorized marketing agent for Captique dermal filler in the United States.